Home Featured Page 11

Featured

Latest

Did New Jersey Really Just Legalize Psilocybin?

Psychedelic Funding, Public Markets, and M&A in 2025

Op-Ed: Beyond Clinical Trials: Psychedelic-Assisted Therapy in Europe’s Real World

The Psychedelic News Feed: January 12 – 18, 2026

Australia’s Psychedelic Experiment: Progress, Pitfalls, and What Comes Next

Bridging Worlds: Psychedelics, Community, and the Work of Our Time

Pα+ Psychedelic Bulletin #207: Lykos Rebrands to Resilient; Pharma Pushes Back...

Matt Xavier -The Psychedelic DJ

AbbVie to Acquire Gilgamesh’s Bretisilocin for Up to $1.2B

Norway Approves Public Funding for Generic Ketamine in Treatment-Resistant Depression

July 2025 Psychedelic Patent Update

Dr Case Newsom – Creating Safe Spaces: The Zendo Project’s Approach...

The Psychedelics & Pain Symposium 2025

Growing Attention To Psychedelics For Pain, Physical & Neurological Conditions

Kat Murti – Students for Sensible Drug Policy, Meta Censorship, and...

1...101112...306 Page 11 of 306

Did New Jersey Really Just Legalize Psilocybin?

Psychedelic Funding, Public Markets, and M&A in 2025

Op-Ed: Beyond Clinical Trials: Psychedelic-Assisted Therapy in Europe’s Real World

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Did New Jersey Really Just Legalize Psilocybin?

Psychedelic Funding, Public Markets, and M&A in 2025

Op-Ed: Beyond Clinical Trials: Psychedelic-Assisted Therapy in Europe’s Real World

The Psychedelic News Feed: January 12 – 18, 2026

Australia’s Psychedelic Experiment: Progress, Pitfalls, and What Comes Next

Bridging Worlds: Psychedelics, Community, and the Work of Our Time

Pα+ Psychedelic Bulletin #207: Lykos Rebrands to Resilient; Pharma Pushes Back...

Matt Xavier -The Psychedelic DJ

AbbVie to Acquire Gilgamesh’s Bretisilocin for Up to $1.2B

Norway Approves Public Funding for Generic Ketamine in Treatment-Resistant Depression

July 2025 Psychedelic Patent Update

Dr Case Newsom – Creating Safe Spaces: The Zendo Project’s Approach...

The Psychedelics & Pain Symposium 2025

Growing Attention To Psychedelics For Pain, Physical & Neurological Conditions

Kat Murti – Students for Sensible Drug Policy, Meta Censorship, and...

EDITOR PICKS

Did New Jersey Really Just Legalize Psilocybin?

Psychedelic Funding, Public Markets, and M&A in 2025

Op-Ed: Beyond Clinical Trials: Psychedelic-Assisted Therapy in Europe’s Real World

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY